Mainz Biomed has partnered with Liquid Biosciences to extend the use of EMERGE in its product development pipeline. This includes analysis of its eAArly DETECT study and the forthcoming U.S. pivotal FDA PMA trial (ReconAAsense). If successful, this will allow Mainz Biomed to advance its current test's capabilities and commercialize a next-generation colorectal cancer screening tool. The eAArly DETECT clinical trial is enrolling 265 subjects across 22 sites and is expected to report results in Q4 2023.